Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

Andreas Emmenegger's Career and Achievements

Andreas Emmenegger joins Swiss Rockets AG with an impressive career spanning over three decades in finance and strategic management across various industries. He has a comprehensive background in private and public financing, capital markets, IPOs on SIX and Nasdaq, M&A, business and corporate development, financial planning, human resources, legal and IT, making him a valuable asset to Swiss Rockets AG.
 
Before joining Swiss Rockets AG, Andreas served as the Chief Financial Officer at Owkin, a prominent AI-powered healthcare company, where he played a pivotal role in strategic planning, business development, and investor relations. 

Previous Executive Roles and Entrepreneurial Ventures

Prior to Owkin, Andreas held the position of Chief Financial Officer at Molecular Partners AG in Zurich for nearly 16 years. As a founding investor and CFO, he was instrumental in raising private and public equity and orchestrating IPOs on both the SIX Swiss Exchange and Nasdaq. Molecular Partners AG is renowned for its innovative work in the discovery and development of DARPins, a novel class of binding proteins.
 
Andreas also co-founded PIQUR Therapeutics AG, a Swiss biopharmaceutical company focused on developing small molecule therapeutics for cancer and inflammatory diseases. His role as a co-founder and board member was crucial in steering the company’s strategic direction and operational excellence.

Strategic Roles in Industry Giants

In addition to his entrepreneurial endeavors, Andreas held key financial roles at major corporations, including Head of Strategic Alliance Finance at Roche and Genentech, Chief Financial Officer at Glycart Biotechnology AG (trade sale to Roche), and CFO positions at The Fantastic Corporation and Interroll Group. His efforts in these roles were key in driving successful M&A transactions, IPOs, and strategic restructurings.

„With Andreas Emmenegger on board, Swiss Rockets AG is poised to further its mission of accelerating the growth of biotech startups and fostering innovation in the biotech sector. His extensive expertise and strategic vision will undoubtedly contribute to the company’s continued success and expansion“, says Dr. Vladimir Cmiljanovic, CEO and Founder of Swiss Rockets AG.

Acknowledgment of Albert Muntane’s Contributions 

Swiss Rockets AG would also like to take this opportunity to express our deep gratitude to Albert Muntane, who has served as our CFO with dedication and excellence. Under his financial leadership, the company has achieved significant milestones. We would like to personally thank Albert for his unwavering commitment and the tremendous efforts he has invested in our company's success. We are pleased to announce that Albert will remain an integral part of our team, continuing to support finance as an advisor to Andreas Emmenegger.